Article

QLT considers selling assets

Vancouver, British Columbia-Biopharmaceutical company QLT Inc. has hired investment bank Goldman, Sachs & Co. to advise the company on maximizing shareholder value, including a possible sale of part or all of the company’s assets. A special committee of the company’s board also has appointed Morrison & Foerster LLP as legal counsel to report directly to the committee as it considers various alternatives.

Vancouver, British Columbia-Biopharmaceutical company QLT Inc. has hired investment bank Goldman, Sachs & Co. to advise the company on maximizing shareholder value, including a possible sale of part or all of the company’s assets. A special committee of the company’s board also has appointed Morrison & Foerster LLP as legal counsel to report directly to the committee as it considers various alternatives.

“The board of directors believes that the net value of the assets of the company exceeds the value represented by the stock price,” said Boyd Clarke, QLT’s chairman. “We had hoped to address that disconnect through the deployment of our current strategic plan. However, as the gap continues to widen, we have decided that, other than as contractually required, making significant additional investments in all of our current products and technologies would be inconsistent with our objective of maximizing shareholder value. As a result, with the help of external financial advisers, we are exploring all strategic options, which may include sale of all or part of the assets of the company.”

QLT’s research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. Using three technology platforms-photodynamic therapy, a drug-delivery system (Atrigel) consisting of biodegradable polymers dissolved in biocompatible carriers, and punctal plugs with drugs-the company has created products to treat wet age-related macular degeneration (Visudyne) and other diseases.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.